Please login to the form below

Not currently logged in
Email:
Password:

Dr Gopalan Narayanan joins VCLS

He takes up a 'disruptive biologics' role at the product development consultancy

Product development consultancy Voisin Consulting Life Sciences has appointed Dr Gopalan Narayanan as vice president, disruptive biologics.

He brings over 18 years of experience as a pharmaceutical physician to the role, which will see him provide strategic advice to developers of complex biologics.

Dr Narayanan said: “Advanced therapy medicinal products present unique scientific and regulatory challenges requiring tailored solutions to fulfill their promise. I am delighted to be part of an organisation which is leading this very exciting future direction of medicine.”

With a focus on advanced therapies and other biologics, he was at UK medicines regulator the MHRA for nearly 12 years as an expert medical assessor and during that time spent four years as the head of its biologicals unit.

Founder and CEO of VCLS Dr Emmanuelle Voisin said: “The appointment of Dr Narayanan further enhances VCLS’s ability to support biotechnology companies throughout ATMP research and development, and lead scientific interactions with regulators and payers. Narayanan’s considerable experience strengthens our capabilities to provide clients with a global perspective, at the forefront of scientific innovation.”

In his new role, Dr Narayanan will deliver strategic direction, specifically in advanced therapy medicinal products, for the company.

14th March 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Dimitri Azzopardi
Case-study for thalassaemia: Dimitri Azzopardi
An in-depth look at beta thalassaemia for Rare Disease Day...
Delivering change through better rare disease communications
OPEN Health’s Richard Jones, Gemma Allen and Charlotte Richards discuss how pharma can utilise tools, channels and stakeholders to deliver change and enable better outcomes....
Interim analysis clinical trials
Assessing the value of interim analyses in clinical trials
Why its important and when its needed...

Infographics